Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Capital Expenditures (2016 - 2025)

Lisata Therapeutics' Capital Expenditures history spans 10 years, with the latest figure at $28000.0 for Q1 2025.

  • For Q1 2025, Capital Expenditures changed N/A year-over-year to $28000.0; the TTM value through Dec 2025 reached $28000.0, changed N/A, while the annual FY2025 figure was $28000.0, N/A changed from the prior year.
  • Capital Expenditures reached $28000.0 in Q1 2025 per LSTA's latest filing, down from $123000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $28000.0 in Q1 2025 to a low of $28000.0 in Q1 2025.